Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synergistic Approach of Continuous Fludarabine, Cytarabine and Etoposide for Relapsed or Refractory Acute Myeloid Leukemia
KCT0003694Phase 2Recruiting
- Sponsor
- Gachon University Gil Medical Center
- Start
- Jan 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, cytarabine, etoposide in acute myeloid leukemia (AML), sponsored by Gachon University Gil Medical Center. Started Jan 2019; status: recruiting.
02
Drugs
fludarabinecytarabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0003694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003694.